This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
::
Journal Watch
Milestones, Perspectives

SDGs – Support

Gates Foundation Announces $1.27B in Health and Development Commitments to Advance Progress Toward the Global Goals
NEW YORK (September 21, 2022) – During United Nations General Assembly week, the Bill & Melinda Gates Foundation—alongside governments, philanthropies, the private sector, NGOs, and global and community leaders—announced commitments totaling $1.27B to improve and save millions of lives.

The funding will address overlapping global crises that have reversed the progress already made toward achieving the UN Sustainable Development Goals (Global Goals). The foundation’s sixth annual Goalkeepers Report notes that nearly every indicator of the Global Goals is off track at the halfway point for achieving them by 2030. Despite these challenges, the report highlights opportunities to accelerate progress by investing in long-term solutions and innovative approaches to entrenched issues, including poverty, inequality, and climate change.

“This week has underscored the urgency of the challenges we face, and the promise of sustainable solutions that save and improve lives,” said Mark Suzman, Gates Foundation CEO. “We can get back on track toward the SDGs, but it’s going to take a new level of collaboration and investment from every sector. That’s why our foundation is significantly stepping up our commitment to help confront crises now and ensure long-term impact across critical determinants of health and development.”...

Accelerating Progress Toward Global Goals

The Bill & Melinda Gates Foundation announced the following commitments this week:
▪ $912 million pledge to the Global Fund to Fight AIDS, Tuberculosis and Malaria
This is the foundation’s largest commitment yet to the Global Fund. Since 2002, health programs supported by the Global Fund partnership have saved 50 million lives. This funding will help accelerate efforts to end HIV, TB, and malaria by 2030 and build resilient health systems needed to protect against future pandemics. It also will be instrumental in reducing the disproportionate impact of these diseases on women and girls.

▪ $100 million to help alleviate the food crisis disproportionately impacting communities in Africa and South Asia and address its underlying causes
This funding will go to:
- The Global Agriculture and Food Security Program (GAFSP) to support national governments in rebuilding resilient, sustainable local food systems
- The African Fertilizer and Agribusiness Partnership (AFAP) to make fertilizers affordable and accessible for smallholder farmers
- The CGIAR’s Nigeria-based International Institute of Tropical Agriculture research center to accelerate work that is already supplying farmers with improved and new varieties of crops, such as beans high in iron; sweet potatoes naturally rich in vitamin A; and naturally hardy cassava, millet, and sorghum
- Working with partners to supply sustainable feed and fodder to African families that depend on livestock as a critical source of income and nutrient-dense food
- Working with partners to strengthen local food systems by empowering women farmers with the tools and resources they need to succeed and support their communities

- In addition, the foundation will double its previous commitment to the Child Nutrition Fund—from $10 million to $20 million. Our investment will support the fund’s expansion beyond ready-to-use therapeutic food to include preventative nutrition products for both women and children.

- $200 million to expand global Digital Public Infrastructure
  This funding will help expand infrastructure that low- and middle-income countries can use to become more resilient to crises such as food shortages, public health threats, and climate change, as well as to aid in pandemic and economic recovery. This infrastructure encompasses tools such as interoperable payment systems, digital ID, data-sharing systems, and civil registry databases.

- $50 million to Partners in Health Scholarship Fund to attend the University of Global Health Equity (UGHE) in Rwanda
  This commitment will help catalyze efforts to raise $200 million. The scholarship fund will support students, 70% of whom are women, to attend UGHE and help accelerate efforts to increase the number of health care workers in Rwanda and around the world.

::::::::::

Africa

Call To Action: Africa’s New Public Health
Africa Centres for Disease Control and Prevention (Africa CDC), African Union Commission
22 September 2022


MINDFUL that Africa, a continent of more than 1.2 billion people, continues to experience the highest incidence of public health emergencies annually.

DEEPLY CONCERNED by the detrimental impact of the ongoing COVID-19 pandemic across Africa’s health, social and economic sectors;

FURTHER CONCERNED by the potential negative consequences of existing public health emergencies including the Monkeypox outbreak.

COGNIZANT of the challenges that African Union Member States face in accessing essential medical countermeasures during the COVID-19 pandemic and other outbreaks, driven by trade and intellectual property-related restrictions.

NOTING the critical shortage of health workforce in Africa that is made worse by the numerous public health emergencies, and challenges with securing relevant health tools for their use.

RECALLING the African Union Assembly Decision Assembly/AU/Dec.835(XXXV) to grant autonomy to
the Africa Centers for Disease Control and Prevention (Africa CDC) and upgrade the current “AU COVID-19 Response Fund” into the “Africa Epidemics Fund” to mobilize resources for preparedness and response to disease threats on the continent.

FURTHER RECALLING the African Union Assembly Decision Assembly/AU/Dec.735(XXXII) that adopted the treaty for the establishment of the Africa Medicine Agency (AMA).

RECOGNIZING the African Union initiative to expand Africa’s manufacturing of vaccines, diagnostics and therapeutics, and

APPLAUDING the commitment, dedication and progress demonstrated by several African Union Member States on building local manufacturing capacity.

APPRECIATING the progress made by the Africa CDC’s Saving Lives and Livelihoods Initiative in partnership with Mastercard Foundation, creating access to COVID-19 vaccines for millions of Africans, and strengthening vaccination capacity to support Africa’s health security agenda.

WE, the Heads of States and Government hereby Call for the full implementation of Africa’s New Public Health Order, which includes:

- Call upon African Union Member States to provide full support to African institutions for public health, including Africa CDC and AMA, in execution of their mandates.
- Call upon governments, multilateral organizations, philanthropies, private sector, and civil society organizations to support institutional capacity-building initiatives targeting all institutions that support public health at the continental and national levels.
- Call upon the African Union Commission to expedite full operationalization of the Africa CDC and AMA.

- Call upon governments, multilateral organizations, philanthropies, private sector, and civil society organizations to support Africa CDC’s efforts and initiatives for building the capacities and capabilities of all workers who contribute to public health in Africa.
- Call upon African Union Member States and all partners to expand and strengthen Community Health Workers programmes in Africa.

[3] Expanding Local Manufacturing of Health Products
- Call upon African Union Member States to coordinate with Africa CDC and the African Union, as they expand manufacturing capacity and opportunities for all health products in Africa.
- Call upon African Union Member States to coordinate with Africa CDC, the African Continental Free Trade Area (AfCFTA) Secretariat and the African Union, in coordinating increased demand for health products manufactured on the continent.
- Call upon all vaccines purchasing mechanisms, such as the Global Alliance for Vaccination and Immunization (GAVI), multilateral institutions, philanthropies, and other stakeholders, to purchase at least 30 per cent of their vaccines from manufacturers in Africa.
- Call upon governments, multilateral organizations, philanthropies, private sector, and civil society organizations to remove trade and intellectual property-related barriers to support local production of health products in Africa.

[4] Increasing Domestic Investment in Health
- Call upon African Union Member States, Africa CDC, the African Union, philanthropies, and private sector to promote innovative domestic financing mechanisms including public-private partnerships.
[5] Promoting Action-Oriented and Respectful Partnership
- Call Upon multilateral organizations, philanthropies, private sector, civil society organizations and all stakeholders to develop action-oriented partnerships, with Africa CDC, the African Union, and AU Member States, which are based on Africa's priorities.
- Call Upon African Union Member States, multilateral organizations and civil society to ensure that Africa’s voice is heard and African positions on the global health security agenda are reflected in the ongoing negotiations for developing international legally binding instrument on pandemic preparedness and response.
- Call upon international partners, development finance institutions, philanthropies and private sector to support investment in infrastructure for manufacturing of health products in Africa, through new and innovative mechanism.
- Call upon Africa CDC and the African Union to strengthen scientific and technical cooperation with relevant African institutions.

Global Fund

Global Fund Private Sector Partners Pledge Record Levels of Support to End AIDS, TB, Malaria and Strengthen Systems for Health
21 September 2022
- Over US$1.23 billion in pledges, up from US$1.13 billion from the Sixth Replenishment.
- US$136 million for catalytic initiatives designed to accelerate progress across a range of crucial areas, from digital health to laboratory systems to community health workers.
- US$250 million in innovative finance investments to support access to innovation and increase domestic capacity.
- More than US$30 million in vital non-financial resources and capabilities to support digital health, build stronger supply chains and improve behavior change approaches and prevention programs.

NEW YORK – At the Global Fund’s Seventh Replenishment Conference, private sector partners committed more funding, in-kind support and catalytic investment than ever before to end the three deadly diseases. This commitment and strong call to action for other partners to join in was led by the Bill & Melinda Gates Foundation, who committed a record US$912 million, and (RED), who pledged US$150 million. With 11 private sector partners continuing their support and 16 new partners pledging for the first time, the total funding pledged grew to US$1.23 billion, an increase of US$108 million over the Sixth Replenishment.

Pledges included financial support from:
- Rotary Australia World Community Service (US$4.8 million)
- AIDS Healthcare Foundation (US$10 million)
- Comic Relief US (US$6 million)
- Nu Thuy Duong (US$3 million)
- Catholic Relief Services (US$3 million)
- Takeda (JPY 376 million)
- Plan International (US$2.3 million)
- GSK and ViiV Healthcare (GBP 2 million)
Global Fund Partners Pledge Record Level of Support to End Deadly Diseases, Prevent Future Pandemics
21 September 2022
NEW YORK / GENEVA - The United States of America-hosted pledging conference for the Global Fund to Fight AIDS, Tuberculosis and Malaria raised more than US$14.25 billion so far for the partnership’s work over the next three years. The conference in the margins of the UN General Assembly brought together more than 45 countries (including 18 Heads of State and Government), multilateral partners, private sector companies and civil society and community organizations. This support aims to save 20 million lives, avert 450 million new infections, and bring new hope for ending AIDS, TB and malaria. This investment will also strengthen health and community systems to leave no one behind and be resilient to future shocks.

Today marks the culmination of a successful campaign that started in February at the Preparatory Meeting co-hosted by the Democratic Republic of the Congo, Republic of Kenya, Republic of Rwanda, Republic of Senegal and Republic of South Africa. All five countries have a long history of being strategic partners of the Global Fund, as both implementers and donors.

“At a moment when the world is confronted by acute economic and political challenges and climate-driven disasters, President Joe Biden delivered an unparalleled mobilization of resources for global health,” said Peter Sands, Executive Director of the Global Fund. “We are extremely grateful for the generosity of everyone who has committed to support our partnership. With the intersection of so many global crises, our donors understand that it is more important than ever to stop these deadly diseases and protect everyone, regardless of who they are or where they live, from these and future health threats.”...

The Global Fund Signs Agreement with Pfizer to Expand Access to PAXLOVID™ Antiviral
22 September 2022
GENEVA - The Global Fund to Fight AIDS, TB and Malaria has signed an agreement with Pfizer for the procurement of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™.

Thanks to partner collaboration through the Access to COVID-19 Tools Accelerator (ACT-Accelerator), all 132 countries eligible for Global Fund grants will have access to PAXLOVID™, subject to local regulatory approval or authorization. The Global Fund, together with ACT-A partners, is also monitoring developments from generic manufacturers to further improve access to antivirals for vulnerable populations in low- and middle-income countries.

“This is an important step to scaling up equitable access to COVID-19 testing and treatment to save lives among the most vulnerable populations, and to ensure preparedness in the event of future co-variants and surges,” said Peter Sands, Executive Director of the Global Fund.
The deal is based on a recommendation by WHO for nirmatrelvir/ritonavir, sold as PAXLOVID™, for mild and moderate COVID-19 patients at highest risk of hospital admission.

“Equitable access to COVID-19 treatments is an absolutely essential part of our toolkit to fight COVID-19,” said Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization. “We have been calling on industry to work with us to facilitate this access, and welcome this important step forward. We know that nirmatrelvir/ritonavir (Paxlovid) reduces the likelihood that a person at high-risk of severe disease will need to be hospitalized. This is important everywhere, as it could help to decrease the number of avoidable deaths – especially in countries with low vaccination coverage.”...

::::::

Pandemic – Equitable Access to Vaccines, Tests, Treatments

**WHO Director-General's opening remarks at the UNGA UNSG-hosted event: “Ending the pandemic through equitable access to COVID-19 vaccines, tests and treatments” – 23 September 2022**

*Speech*

23 September 2022

Excellencies, dear colleagues and friends, I thank Secretary-General Guterres for bringing us together today, and for his leadership.

We have never been in a better position to end COVID-19 as a global health emergency, as Prime Minister De Croo of Belgium said. The number of weekly reported deaths is near the lowest since the pandemic began; And two-thirds of the world’s population is vaccinated, including 75% of health workers and older people.

But these encouraging global numbers mask disparities that put us all at risk. Only 19% of the population of low-income countries are vaccinated, compared with 75% in high-income countries.

A new report published yesterday by the ACT Accelerator Council highlights falling testing rates globally, virtually non-existent access to new antivirals in most low- and middle-income countries, and outlines what needs to be done to close these gaps.

These inequities are not just a risk for those they affect directly; they are a risk for all of us. So closing them is essential if we are to truly end the pandemic. Through the ACT Accelerator, we have made good progress:

:: Since last year’s UNGA meeting, COVAX has delivered almost 1.5 billion vaccine doses, supporting 68 new countries to reach vaccination coverage of at least 40%.
:: Coverage in the COVAX AMC countries has almost doubled this year, to more than 50%;
:: Access to medical oxygen has increased;
:: And just yesterday, our partners at the Global Fund announced an agreement with Pfizer to facilitate access to Paxlovid through the ACT Accelerator.

But there is much more to be done. We have the tools to bring the acute phase of this pandemic to an end. But only if we vaccinate all health workers and older people, keep testing, and expand access to
effective antivirals. That doesn’t mean the virus will go away; it means countries will be able to transition to managing it alongside other respiratory diseases.

In the same way, in the coming months the partners of the ACT Accelerator will also integrate COVID-19 into the regular work of our organizations, to ensure countries can continue to access vaccines, tests and treatments over the long-term.

Our partnership has provided a powerful platform for collaboration, and important lessons for the future, as we look to build a stronger architecture for health emergency preparedness and response. Let me leave you with three priorities:

First, I echo the Secretary-General’s call that together we must close the vaccination gap, especially among the most at-risk.
Second, I urge all countries to increase surveillance, testing and sequencing;
And third, we must ensure that life-saving antivirals are available everywhere.

We’re not there yet, but the end is in sight. A marathon runner does not stop when the finish line comes into view; she runs harder, with all the energy she has left. So must we. Now is the time for all of us to run harder and make sure we cross the line and reap the rewards of all our hard work.

No time for COVID-19 complacency, say key countries responsible for tracking global rollout of COVID-19 vaccines, tests and treatments

Statement - 22 September 2022

- Warning comes from Norway and South Africa on behalf of the ACT-Accelerator Facilitation Council, as rollout of medical countermeasures and other tools stagnate
- Emphasizing the global pandemic is not over, they say coordinated action, funding and political commitments are key to saving lives and preventing economic, health and societal damage from COVID-19
- New report from Council’s Diagnostics and Therapeutics Working Group sets out key recommendations for improving access to COVID-19 tests and treatments

Tracking and accelerating progress to reach everyone, everywhere

As the third UNGA of the COVID-19 pandemic reaches its conclusion, many countries are far from meeting global targets on vaccination coverage, testing rates, and access to treatments and PPE. The co-chairs of the ACT-Accelerator’s Council Tracking and Accelerating Progress working group warn that coordinated action, sustained political will and funding commitments are still needed, to save lives and combat the ongoing threat of COVID-19.

The group – co-chaired by Indonesia and the United States - is responsible for tracking progress toward the global COVID-19 targets for access to vaccines, diagnostics, treatments, and PPE, under the umbrella of the ACT-Accelerator equitable access partnership.

Ahead of several high-level events at the UNGA to take stock of progress, Indonesia’s Tri Tharyat and the United States’ Loyce Pace highlight that while progress is being made, the global threat of COVID-19 is far from over, particularly for high-risk groups in lower-income countries. According to the most recent Global COVID Access Tracker data, around a quarter of those most
vulnerable globally still need a primary COVID-19 vaccination series (24% of elderly persons and 26% of health workers).

Indonesian Ambassador Tri Tharyat, Director General for Multilateral Cooperation at the Ministry of Foreign Affairs said “Critical funding and political leadership is needed for the roll-out of tests, treatments and vaccines. Funding the ACT-Accelerator will support its work to expand access to life-saving tools, from new oral antivirals to booster vaccine doses, to ensure healthcare workers and those who are most at-risk are protected wherever they live in the world. We must quickly translate vaccines into vaccination. No-one is safe until everyone is safe.”

The Working Group notes with concern:
- COVID-19 vaccination rates in low-income countries stand at 19%, compared to almost 75% in high-income countries.
- Low income and lower-middle income countries are still far from the 100 tests per 100k population per day target; low-income countries are testing at a rate of just 2/100k population, while lower-middle income countries are at 22/100k population.
- The roll-out of new lifesaving COVID-19 treatments including oral antivirals in low and lower-middle income countries remains limited or non-existent.
- Equitable access to these COVID-19 countermeasures and preparation for the delivery is critical for countries to integrate the management of the virus into their primary health systems, as part of a longer-term strategy.

Loyce Pace, Assistant Secretary for Global Affairs at the U.S. Department of Health and Human Services, said: “Support for vaccine readiness and uptake are making an important difference to increase COVID-19 vaccine coverage and significantly reduce the number of countries with very low COVID-19 vaccination rates. Primary series coverage in the COVAX AMC 92 countries increased from 28% in January of 2022 to 51% in September. There is still progress to be made in global vaccination rates and lessons for how successful efforts might apply to testing or treatment initiatives at the country level.”

Access to tests and treatments key for those at highest risk

As a report on access to COVID-19 tests and treatments is published today, the co-chairs of the council’s Therapeutics and Diagnostics Working Group, Mustaqueem de Gama of South Africa and Ian Dalton of the United Kingdom, highlight the decline in testing rates and the lack of equitable access to new antiviral treatments for COVID-19.

The Working Group report emphasizes that diagnostics and therapeutics, and associated test-to-treat strategies, are fundamental components of pandemic response, both for COVID-19 and future health threats. The report makes sixteen recommendations for action for medium and long-term COVID-19 control, as well as the strengthening of prevention, preparedness and response (PPR).

Mustaqueem De Gama, Director of Legal International Trade at South Africa’s Department of Trade, Industry and Competition said: “The swift, equitable roll-out of vaccines, tests, and treatments is crucial to help countries combat COVID-19. Without adequate testing and sequencing, the world is blind to the evolution of the virus and potential new variants. People in low and middle-income countries continue to die due to a lack of access to antiviral treatments and oxygen. We must push on for equitable access to COVID-19 tools, despite multiple competing priorities.”
Ian Dalton, Senior Head of Pharmaceuticals and Diagnostics at the UK’s Foreign, Commonwealth and Development Office said: “As the report shows, investments in diagnostics and therapeutics capacity for COVID-19 pays dividends for future pandemic prevention, preparedness and response. There are action points to be taken forward from the analysis undertaken by the working group, and I hope partners will see it as a springboard for action.”

Professor Olive Shisana, President’s Special Advisor on Social Policy, South Africa, said: “The pandemic continues to pose a threat to lives and livelihoods, especially in Africa, where millions of people are still unvaccinated and do not have access to new antiviral treatments. Now is not the time for complacency, but instead time to act together in solidarity, to ensure access for everyone, everywhere.”

ACT-Accelerator Facilitation Council Working Group Report on Diagnostics and Therapeutics
22 September 2022 | Publication :: 38 pages
PDF: Download (3.7 MB)

Overview
The COVID-19 pandemic requires a complete public health response that spans non-pharmaceutical interventions and medical countermeasures to mitigate the impact of the virus on lives and livelihoods. Despite this need, the equitable roll-out of COVID-19 diagnostics and therapeutics continues to be inadequate and threatens to undo public health gains achieved throughout the pandemic.

This report’s central premise is that diagnostics and therapeutics, and associated test to treat strategies, are fundamental components of the pandemic response, both for COVID-19 and for future health threats. Two years into the COVID-19 pandemic, this report reflects on the main challenges and key solutions on the road to equitable access to diagnostics and therapeutics.

This report draws from experience gained through the Access to COVID-19 Tools (ACT) Accelerator Diagnostics and Therapeutics pillars, and includes the perspectives of collaborating stakeholders (countries, civil society representatives and the private sector). Building on these findings, this report proposes sixteen recommended actions to address what have been identified as key structural challenges and specifies a potential owner for each action. The report offers a potential high-level roadmap of where efforts should be concentrated to support country-level decision-making.

“Pandemic Treaty”

Second round of public hearings in relation to a new international instrument on pandemic prevention, preparedness and response

During a Special Session of the World Health Assembly held in December 2021, WHO Member States agreed to establish an intergovernmental negotiating body (INB) to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness and response.
The first round of the public hearings was held on 12-13 April 2022. The second round will be held on 29-30 September 2022. For the second round of public hearings, interested parties were invited to submit a video statement between 9 and 16 September. The request was for videos of no more than 90 seconds, in response to the question:

"Based on your experience with the COVID-19 pandemic, what do you believe should be addressed at the international level to better protect against future pandemics?".

Two compilations of the video statements will be broadcast from the WHO website:
- 29 September: 09:00-12:00 CET
- 30 September: 18:00-21:00 CET

Introductory and concluding remarks will be made by the WHO Director-General, Dr Tedros Adhanom Ghebreyesus, and the Co-Chairs of the INB, Ms Precious Matsoso of South Africa and Mr Roland Driece of the Netherlands.

Watch the broadcast

---

**PHEIC**

**Monkeypox**

*Public Health Emergency of International Concern (PHEIC)*

https://www.who.int/emergencies/situations/monkeypox-outbreak-2022

---

**Multi-country outbreak of monkeypox, External situation report #6 - 21 September 2022**

---

**Figure 1. Epidemiological curve of weekly aggregated confirmed cases of monkeypox by region, from 1 January to 17 September 2022 17:00 CEST**

---

*Source: WHO*
Weekly Epidemiological and Operational updates
Last update: 16 Sep 2022

Confirmed cases :: 611 421 786
Confirmed deaths :: 6 512 438
Vaccine doses administered: 12 640 866 343

Weekly epidemiological update on COVID-19 – 21 September 2022

Overview
Globally, the number of new weekly cases remained stable during the week of 12 to 18 September 2022 as compared to the previous week, with over 3.2 million new cases reported. The number of new weekly deaths decreased by 17% as compared to the previous week, with over 9800 fatalities reported.

As of 18 September 2022, over 609 million confirmed cases and over 6.5 million deaths have been reported globally.

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 07 July 2022
[New additions; Full scale view available at title link above]
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 24 Sep 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

| 41 vaccines approved for use by at least one national regulatory authority | 11 vaccines in WHO’s Emergency Use Listing |
| 1.76bn doses shipped through COVAX to 146 countries | $2 – $40 reported vaccine price range per dose |
| 17.6bn doses secured globally | 21K novel oral antiviral therapeutic treatments arrived in 1 countries |

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 24 Sep 2022]: [https://data.undp.org/vaccine-equity/](https://data.undp.org/vaccine-equity/)
See also visualization on Vaccine Access and Vaccine Affordability

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as
such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Duke – Launch and Scale Speedometer

**The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research

See our COVID Vaccine Manufacturing research

See our COVID Vaccine Donations & Exports research
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
24 Sep 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 120M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.7B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 350M
Other Delivered (Number of Doses): 390M
Total Delivered (Number of Doses): 740M
Total Administered (Number of Doses): 500M

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 24 Sep 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

Our World in Data

**Coronavirus (COVID-19) Vaccinations** [Accessed 24 Sep 2022]

:: 67.9% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.7 billion doses have been administered globally, and 4.25 million are now administered each day.
:: Only 22.3% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

**HHS**

*News*

**HHS Announces Initiative to Help Uninsured and Underinsured Americans Access COVID-19 Monoclonal Antibody Treatment**
September 23, 2022 | *News Release*

**FDA**

*Press Announcements*

**September 23, 2022 - New FDA Draft Guidance Aims to Protect Children who Participate in Clinical Trials**

The draft guidance, “Ethical Considerations for Clinical Investigations of Medical Products Involving Children,” describes the ethical framework for protecting children in clinical research, which includes...
risk and benefit considerations. The draft guidance outlines and explains fundamental concepts for the ethical framework that IRBs, sponsors and industry should consider when reviewing or conducting clinical trials involving children, including:

- Scientific necessity of conducting a clinical investigation in children
- Risk categories for interventions or procedures that do not offer a prospect of direct benefit to the child
- How to evaluate whether an intervention or procedure offers a prospect of direct benefit to the child
- Assessment of risk for interventions or procedures with a prospect of direct benefit
- Component analysis of the risks of interventions or procedures
- Potential for review, under a regulatory provision, of research that is not otherwise approvable by an IRB
- Parental or guardian permission and child assent

The public can provide comments on the draft guidance.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022

News 16/09/2022

...COVID-19 update

Since the CHMP meeting in July, several recommendations related to COVID-19 vaccines and therapeutics were made.

- Authorising use of Nuvaxovid as a booster dose for adults who have had Nuvaxovid, an mRNA vaccine or an adenoviral vector vaccine as their primary vaccination. (The recommendation was made on 1 September 2022)
- Authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19. For more information, see the news announcement. (The recommendation was made on 1 September 2022)

COVID-19 recommendations adopted during the present meeting of the CHMP:

- Authorising the adapted bivalent vaccine Comirnaty Original/Omicron BA.4-5 for use in people aged 12 years and above who have received at least a primary course of vaccination against COVID-19. This vaccine is an adapted version of the mRNA COVID-19 vaccine Comirnaty and targets the Omicron subvariants BA.4 and BA.5 in addition to the original strain of SARS-CoV-2. For more information, see the news announcement.
- Converting the conditional marketing authorisations of the COVID-19 vaccines Comirnaty and Spikevax into standard marketing authorisations. CHMP considered that the additional studies conducted by the companies as part of their post-authorisation obligations have provided ample information on the vaccines’ protection against COVID-19, as well as their quality and safety. For more information, see the news announcement.
- Approving a new manufacturing site in Dessau-Rosslau, Germany, for COVID-19 Vaccine Valneva.
- Authorising booster doses of Comirnaty for children from 5 to 11 years of age.
- Extending the use of COVID-19 therapeutic Evusheld for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen.
- Extending the use of COVID-19 therapeutic Veklury in two paediatric populations:
  - Paediatric patients (of at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen or other non-invasive ventilation at the start of treatment.
  - Paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

---

**European Centre for Disease Prevention and Control**
https://www.ecdc.europa.eu/en

*Latest Updates [Selected]*

**Weekly COVID-19 country overview**
Epidemiological update - 23 Sep 2022

**Joint ECDC-WHO/Europe monkeypox surveillance bulletin**
Epidemiological update - 21 Sep 2022

**Monkeypox situation update, as of 20 September 2022**
Epidemiological update - 21 Sep 2022

**Monkeypox (MPX) Reporting Protocol 2022**
Guidance - 23 Sep 2022

**Pilot protocol for a COVID-19 vaccine effectiveness study using health data registries**
Guidance - 19 Sep 2022

---

**European Commission**
https://ec.europa.eu/commission/presscorner/home/en

*Latest* [Selected]

**Press release 24 September 2022**

**Global Europe: President von der Leyen announces funding for women and youth’s rights, food security, fight against disease, and biodiversity**

The President of the European Commission, Ursula von der Leyen, has concluded a week of discussions with world leaders and international partners at the UN General Assembly in New York.

**Press release 21 September 2022**

**EU announces historic €715 million for the Global Fund to save millions of lives from AIDS, tuberculosis and malaria***

Today, the European Commission announced a new record €715 million from the EU budget as part of a wider Team Europe pledge to the Global Fund for the period 2023-2025 at the Fund’s Seventh Replenishment Conference, hosted by US President Biden in New York.

---
Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 INDIA as on: 24 September 2022, 08:00 IST (GMT+5:30)
(Status change since yesterday)
Active (0.10%) 44436
Discharged (98.71%) 43990414
Deaths (1.19%) 528487
Total Vaccination: 2,17,41,04,791 (14,76,840 ↑)

Government of India – Press Information Bureau
Latest Press Releases
Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

PHEIC
Polio

Polio this week as of 21 Sep 2022 - GPEI
:: Following the passing of Her Majesty Queen Elizabeth II, the GPEI paid tribute to Her leadership, steadfastness and commitment to service and recognized His Royal Highness King Charles III’s support for polio eradication. Read more...
:: For the last two decades, the prospect of sending 16 visiting polio experts out across the provinces of Afghanistan would have been impossible but from 6 to 19 June 2022, WHO Afghanistan’s polio eradication programme did just that. Their mission? To review the country’s polio surveillance system, assess its functionality at all levels and make specific recommendations for maintaining and improving surveillance quality. Read more...

Summary of new polioviruses this week:
- Afghanistan: one WPV1 case
- Pakistan: two WPV1 cases and one positive environmental sample
- Mozambique: one WPV1 case
- Benin: two cVDPV2 cases and one positive environmental sample
- DR Congo: one cVDPV2 case
- Ghana: one cVDPV2 positive environmental sample
- Madagascar: one cVDPV1 positive environmental sample
- Malawi: two cVDPV1 cases
- Nigeria: one cVDPV2 positive environmental sample


**UN OCHA – Current Emergencies**

*Current Corporate Emergencies*

**Afghanistan**

No new digest content identified.

**Northern Ethiopia**

*Ethiopia - Situation Report, 19 Sep 2022*

**Somalia**

No new digest content identified.

**Ukraine**

*Ukraine: Situation Report - Last updated: 21 Sep 2022*

....Across Ukraine, nearly 580 humanitarian partners have provided life-critical aid and protection services to 13.4 million people.

::::::

::::::

**WHO & Regional Offices** [to 24 Sep 2022]

[https://www.who.int/news](https://www.who.int/news)

*Selected News/Announcements/Statements*

23 September 2022

*News release*

**New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere**

22 September 2022

*Statement*

**No time for COVID-19 complacency, say key countries responsible for tracking global rollout of COVID-19 vaccines, tests and treatments**

22 September 2022

*Departmental news*

**The Global Leaders Group host side event at UN General Assembly on Antimicrobial Resistance (AMR)**

21 September 2022

*News release*

**Heads of State commit to Noncommunicable Disease Global Compact to save 50 million lives by 2030**

21 September 2022

*Departmental news*

**Key highlights from the UN General Assembly side event: Progress and multisectoral action towards achieving global targets to end TB**
Departmental news
Refugee and migrant health at the centre of discussions during the 77th UN General Assembly

WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches
Selected Speeches
23 September 2022
Speech
WHO Director-General’s opening remarks at the UNGA UNSG-hosted event: “Ending the pandemic through equitable access to COVID-19 vaccines, tests and treatments” – 23 September 2022

22 September 2022
Speech
WHO Director-General's opening remarks at the media briefing – 22 September 2022

1 September 2022
Speech
WHO Director-General's remarks at the UN General Assembly Global Fund Replenishment Conference, Pledging Event – 21 September 2022

21 September 2022
Speech
WHO Director-General's opening remarks at first annual gathering of the global group of Heads of State and government group for the prevention and control of noncommunicable diseases – 21 September 2022

20 September 2022
Speech
WHO Director-General’s opening remarks at the UN General Assembly high-level side event "Progress and multisectoral action towards achieving global targets to end TB" – 20 September 2022

20 September 2022
Speech
WHO Director-General's remarks at the UN General Assembly side event "Promoting the health of refugees and migrants: are we on the right path to evidence-informed policymaking?" – 20 September 2022

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
22 September 2022

**WHO bolsters Ebola disease outbreak response in Uganda**

21 September 2022

**WHO validates Malawi for eliminating trachoma, first country in southern Africa**

20 September 2022

**Uganda declares Ebola Virus Disease outbreak**

19 September 2022

**Boosting medical oxygen supplies in the Democratic Republic of Congo**

---

**WHO Region of the Americas** PAHO

:: 23 Sep 2022

**PAHO brings together health authorities from the Americas for its 30th Pan American Sanitary Conference**

Delegates will discuss policies to improve mental health, strengthen genomic surveillance, and recover progress towards achieving the Sustainable Development Goals, among other issues. The Conference will also elect next PAHO Director. Washington, D.C., 23 September 2022 (PAHO/WHO) - Ministers of Health and other high-level representatives...

:: 22 Sep 2022

**The Americas are not on track to meet global targets on maternal health and mortality, PAHO Director says**

New York, NY, 22 September 2022 (PAHO) —Speaking at a high-level event during the United Nations General Assembly side, the Pan American Health Organization (PAHO) Director Carissa F. Etienne highlighted the aggravating effect of COVID-19 on the health of women, children and adolescents in the region, which have placed these groups at greater risk...

:: 21 Sep 2022

**UN awards Brazilian Strategy to Prevent Childhood Obesity – PROTEJA**

Brazil receives the award at the United Nations General Assembly Brasilia, 21 September, 2022 - Brazil receives, this Wednesday (21), the Award from the United Nations Task Force for the Prevention and Control of Chronic Non-Communicable Diseases (NCDs), which this year joined forces with the Special Primary Health Care Program (PHC... 

:: 21 Sep 2022

**As COVID-19 continues to impact the Americas, dwindling vaccination rates leave countries susceptible to polio and other preventable diseases**

Washington D.C. 21 September 2022 (PAHO) – While COVID-19 continues to take around 4,000 lives each week in the Americas, and monkeypox cases rise, the polio virus has now been detected among unvaccinated communities in New York. In light of this, the Pan American Health Organization Director (PAHO) has called on countries to urgently strengthen...

:: 21 Sep 2022

**Heads of State commit to Noncommunicable Disease Global Compact to save 50 million lives by 2030**

Michael R. Bloomberg reappointed as WHO Global Ambassador of Noncommunicable Diseases and Injuries New Gallup survey indicates strong global support for policies outlined in WHO report to combat growing public health burden of noncommunicable diseases Geneva / New York, 21 September 2022 –Today, Dr Tedros Adhanom Ghebreyesus, Director-...

---

**WHO South-East Asia Region** SEARO

:: 23 September 2022   News release
WHO South-East Asia Region polio-free, accelerated efforts needed in view of increased risks: experts

WHO European Region EURO
:: 23 September 2022 News release
Nordic and Baltic countries join WHO/Europe in calling for mental health promotion in COVID-19 recovery
:: 23 September 2022 News release
#Youth4Health: Call for youth voices
:: 22 September 2022 News release
COVID-19 rehabilitation patient leaflet hugely popular
:: 22 September 2022 News release
The personal stories behind the establishment of 2 long COVID groups

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new DONs identified.

WHO Events
https://www.who.int/news-room/events/1
[Selected]
Second round of public hearings in relation to a new international instrument on pandemic prevention, preparedness and response
29 – 30 September 2022

New WHO Publications
https://www.who.int/publications/i
Selected Titles
21 September 2022
Multisectoral coordination mechanisms operational tool: an operational tool of the tripartite zoonoses...

21 September 2022
Surveillance and information sharing operational tool: an operational tool of the tripartite zoonoses...

21 September 2022
**WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents**

19 September 2022

**Capturing the evidence on access to essential antibiotics in refugee and migrant populations**

::::::

::::::

:::

**CDC/ACIP [U.S.] [to 24 Sep 2022]**

http://www.cdc.gov/media/index.html

https://www.cdc.gov/vaccines/acip/index.html

*Latest News Releases*

**CDC announces $90M funding to support Pathogen Genomics Centers of Excellence (PGCoE) network**

Today, CDC announced 5-year awards to five state public health departments. The awards will establish the Pathogen Genomics Centers of Excellence (PGCoE) network.

::::::

**ACIP Meetings**

*Next ACIP Meeting*

October 19-20

::::::

**MMWR Weekly: Current Volume (71)**

*September 23, 2022 / No. 38*

*PDF of this issue*

- Clusters of Rapid HIV Transmission Among Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2018–2021
- Two Cases of Monkeypox-Associated Encephalomyelitis — Colorado and the District of Columbia, July–August 2022
- Health Care Personnel Exposures to Subsequently Laboratory-Confirmed Monkeypox Patients — Colorado, 2022
- Monkeypox in a Young Infant – Florida, 2022
- Notes from the Field: Norovirus Outbreaks Reported Through NoroSTAT — 12 States, August 2012–July 2022

::::::

**Coronavirus Disease 2019 (COVID-19) - CDC**

*Approximately 15 announcements/reports/data summaries.*

::::::

::::::
Africa CDC  [to 24 Sep 2022]
http://www.africacdc.org/

News
Call To Action: Africa’s New Public Health
22 September 2022

Press Releases
Africa CDC and Smart Smart Africa partner to advance Digital Health in Africa
20 September 2022

Press Releases
Uganda Reported an Outbreak of Ebola Virus Disease
20 September 2022


China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China  [to 24 Sep 2022]
http://en.nhc.gov.cn/

News
Sept 24: Daily briefing on novel coronavirus cases in China
On Sept 23, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 188 new cases of confirmed infections.

National Medical Products Administration – PRC  [to 24 Sep 2022]
http://english.nmpa.gov.cn/

Chinese mainland reports 121 new local confirmed COVID-19 cases
2022-09-23
The Chinese mainland on Thursday reported 121 locally transmitted confirmed COVID-19 cases, with Sichuan and Guizhou provinces reporting 43 cases each, according to the National Health Commission’s report on Friday.

CCDC Weekly Reports: Current Volume (4)
2022-09-23 / No. 38  INFECTIONOUS DISEASE ISSUE
View  PDF of this issue
- Preplanned Studies: Age-Specific Pulmonary Tuberculosis Notification Rates — China, 2008–2018
- Perspectives: Neglected Zoonotic Monkeypox in Africa but Now Back in the Spotlight Worldwide
- Perspectives: A Secure Supply of Antiretroviral Medicines for People Living with HIV During the COVID-19 Pandemic — China’s Experience
- Notes from the Field: The First Imported Case of Monkeypox in the Mainland of China — Chongqing Municipality, China, September 16, 2022
Methods and Applications: Development and Application of a Multidrug-Resistant Tuberculosis Case Management System — Yunnan Province, China, 2017–2020

Organization Announcements

Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 24 Sep 2022]
https://alleninstitute.org/news-press/
News
Mapping the whole human brain: Allen Institute to lead global collaboration
September 22, 2022
NIH BRAIN Initiative to fund primate brain atlases, maps of developing mouse brain, coordination and knowledge sharing, and brain function research

BMGF - Gates Foundation  [to 24 Sep 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release
Sep 21, 2022
Gates Foundation Announces $1.27B in Health and Development Commitments to Advance Progress Toward the Global Goals

Press release
Sep 20, 2022
Gates Foundation Honors Four Leaders With 2022 Goalkeepers Global Goals Awards for Their Inspiring Efforts to Drive Progress for All

Bill & Melinda Gates Medical Research Institute  [to 24 Sep 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications
No new digest content identified.

CARB-X  [to 24 Sep 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 24 Sep 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – September 2022 is now posted here
:: Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations  [to 24 Sep 2022]
http://cepi.net/
Latest News
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 24 Sep 2022]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center  [to 24 Sep 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP  [to 24 Sep 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the
development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,
tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-
Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center  [to 24 Sep 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative  [to 24 Sep 2022]
Evidence Aid  [to 24 Sep 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Selected Resources
Initiation and completion of treatment for latent tuberculosis infection in migrants
Added September 23, 2022

Public engagement with pre-incident information materials for initial response to a chemical, biological, radiological or nuclear (CBRN) incident
Added September 22, 2022

Fondation Merieux  [to 24 Sep 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

Gavi [to 24 Sep 2022]
https://www.gavi.org/
News Releases
No new digest content identified

GHIT Fund  [to 24 Sep 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified

Global Fund  [to 24 Sep 2022]
News & Stories
22 September 2022
The Global Fund Signs Agreement with Pfizer to Expand Access to PAXLOVID™ Antiviral
The Global Fund to Fight AIDS, TB and Malaria has signed an agreement with Pfizer for the procurement of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™

21 September 2022
Global Fund Private Sector Partners Pledge Record Levels of Support to End AIDS, TB, Malaria and Strengthen Systems for Health
21 September 2022
**Global Fund Partners Pledge Record Level of Support to End Deadly Diseases, Prevent Future Pandemics**

The United States of America-hosted pledging conference for the Global Fund to Fight AIDS, Tuberculosis and Malaria raised more than US$14.25 billion so far for the partnership’s work over the next three years. The conference in the margins of the UN...

20 September 2022
**Global Fund Approves Emergency Funding to Help Maintain Essential Health Services in Pakistan**

The Global Fund to Fight AIDS, Tuberculosis and Malaria has approved US$10 million in emergency funding to ensure access and distribution of essential medicines and health services in Pakistan.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 24 Sep 2022]**

https://www.glopid-r.org/news/
*News*

*No new digest content identified*

**Hilleman Laboratories**  [to 24 Sep 2022]

http://www.hilleman-labs.org/
*News & Insights*

*No new digest content identified*

**HHMI - Howard Hughes Medical Institute**  [to 24 Sep 2022]

https://www.hhmi.org/news
*Press Room*

*No new digest content identified.*

**Human Vaccines Project**  [to 24 Sep 2022]

http://www.humanvaccinesproject.org/
*News*

*HVP COVID Report*

Sep 22, 2022
**Deepta Bhattacharya: You've Been Vaccinated and Infected. What Now?**

**IAVI**  [to 24 Sep 2022]

https://www.iavi.org/
*Latest News*

*FEATURES*

September 20, 2022
**IAVI scientists publish findings that suggest intranasal vaccination can prevent COVID-19 breakthrough infections in small animal models**
Peter Maurer: The TPNW brings us one step closer to a nuclear-weapon-free-world
22-09-2022 | Statement

Kyrgyzstan/Tajikistan: ICRC calls for the respect of the rules of international humanitarian law
Tashkent (ICRC) - The International Committee of the Red Cross (ICRC) is concerned about the upsurge of military activity along the Kyrgyz-Tajik border and its humanitarian consequences, including its impact on the lives and safety of people residing
19-09-2022 | News release

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
Local solutions to local problems: Reaching zero-dose children in Chad’s nomadic communities
06 Sep 2022
An innovative approach that combines children and animal vaccinations is helping to boost coverage amongst zero-dose children in Chad’s nomadic communities.

IFRC [to 24 Sep 2022]
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 24 Sep 2022]
Press Documents
No new digest content identified.

IOM / International Organization for Migration [to 24 Sep 2022]
News
23 Sep 2022
IOM, UNHCR and UNRWA: Latest Tragedy at Sea off Syria Must Prompt Action

News
23 Sep 2022
20,000th Refugee Resettled to Canada with IOM’s Assistance

ISC / International Science Council [to 24 Sep 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News, Blogs
Strengthening Research Integrity: Improving peer review in publishing
19.09.2022
... A recent occasional paper, Strengthening research integrity: The role and responsibilities of publishing, of the International Science Council’s project on the future of scientific publishing, made two recommendations to improve pre-publication peer review, thereby strengthening research integrity in the published record...

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
Webinar – Kate Schroder – Inflammasome signalling: from fundamental biology to new therapeutics
Monday 26th September 2022 at Online Webinar

IVAC [to 24 Sep 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI [to 24 Sep 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 24 Sep 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
Response to Recommendations on US Policy Governing Potential Pandemic Pathogen and Dual Use Research
September 21, 2022
No new digest content identified.

National Academy of Medicine - USA [to 24 Sep 2022]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 24 Sep 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 24 Sep 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH [to 24 Sep 2022]
http://www.nih.gov/
News Releases
No new digest content identified.

PATH [to 24 Sep 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Rockefeller Foundation [to 24 Sep 2022]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Press Releases
The Rockefeller Foundation Pledges US$15 Million to Global Fund To Fight AIDS, Tuberculosis, and Malaria
New commitment increases the Foundation’s support to US$30 million (2020-2025) for the Global Fund’s efforts to save lives, build resilient and sustainable health systems, and strengthen pandemic preparedness NEW YORK ...
Sep 19 2022
Press Releases

**Arizona State University Launches Evidence Commons, the Only Comprehensive Repository of Covid-19 Tests and Testing Practices Publications**

Evidence Commons streamlines diagnostics related research with more than 3,000 publicly available Covid-19 testing publications to spur scientific collaboration and improve pandemic preparedness

PHOENIX | September 19, 2022 – Arizona State ...

---

**Sabin Vaccine Institute** [to 24 Sep 2022]
https://www.sabin.org/press/

- Latest News & Press Releases
  - No new digest content identified.

---

**UNAIDS** [to 24 Sep 2022]
http://www.unaids.org/en

- Selected Press Releases/Reports/Statements
  - 19 September 2022
  - **PrEParing for the next chapter of HIV prevention in Myanmar**

---

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 24 Sep 2022]

- News Releases
  - **UNHCR and Islamic Solidarity Fund for Development Launch Global Islamic Fund for Refugees**
    - 23 Sep 2022

---

**UNICEF** [to 24 Sep 2022]
https://www.unicef.org/media/press-releases

- Press Releases, News Notes, Statements [Selected]
  - Remarks
    - 23 September 2022
    - **Children in Sudan are in the middle of a perfect storm of crises - UNICEF Geneva Palais briefing**
      - GENEVA/KHARTOUM, 23 September 2022 – “In this briefing, my aim is to underscore the enormity of challenges the children of Sudan face. And to share some sense of what action is urgently required. Children are caught in a perfect storm of crises on top of crises. “More than one out of every three of Sudan’s children are in need of humanitarian...

  - Remarks
    - 22 September 2022
    - **UNICEF Executive Director Catherine Russell’s remarks on how to best respond to the disproportionate impacts of rising food insecurity on women and girls in humanitarian crisis**
NEW YORK, 22 September 2022 - "Excellencies, colleagues, "Welcome to UNICEF House. "Before we kick off our discussions, I would like to thank Her Royal Highness Crown Princess Mary of Denmark and Dame Pauline Tallen, the Honorable Minister for Women Affairs in Nigeria, for bringing global attention to this issue. "Thank you to the Government...

**Remarks**
21 September 2022

**UNICEF Executive Director Catherine Russell's remarks at The Child Malnutrition Crisis: Pledging to Save Lives event**

NEW YORK, 21 September 2022 - "Excellencies, distinguished guests, colleagues, "I am very happy to welcome you to UNICEF for this critical discussion. "I want to begin by thanking Administrator Samantha Power and the United States Government for their unflagging support of the most vulnerable children, and for co-hosting this event. "I am deeply...

**Press release**
21 September 2022

**Over half a billion dollars pledged to tackle severe wasting since July in unprecedented international response to deepening child malnutrition crisis**

NEW YORK, 21 September 2022 — Governments, philanthropies, and private donors have pledged approximately US$577 million since July in response to the deepening child malnutrition crisis – with at least 60 per cent of that amount committed to directly supporting UNICEF’s work. Roughly US$280 million of the over half billion raised was pledged today...

**Unitaid** [to 24 Sep 2022]
https://unitaid.org/

**Featured News**
22 September 2022

**Canada contributes Can$ 25 million to Unitaid to expand sustainable access to medical oxygen**

22 September 2022

**France reconfirms commitment to Unitaid during the Global Fund’s 7th Replenishment Conference**

**Vaccine Equity Cooperative [nee Initiative]** [to 24 Sep 2022]
https://vaccineequitycooperative.org/news/

**News**
No new digest content identified.
Vaccination Acceptance & Demand Initiative [Sabin]  [to 24 Sep 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project  [to 24 Sep 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 24 Sep 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust  [to 24 Sep 2022]
https://wellcome.ac.uk/news
News, Opinion, Reports
No new digest content identified.

The Wistar Institute  [to 24 Sep 2022]
Press Release
Sep. 19, 2022
Wistar Scientists Identify Key Biomarkers that Reliably Predict Response to Immune Checkpoint Inhibitor Therapy for Melanoma
New research finds biological processes that improve prediction of therapeutic performance and provide a framework to develop predictors for this aggressive skin cancer.

WFPHA: World Federation of Public Health Associations  [to 24 Sep 2022]
https://www.wfpha.org/
Latest News - Blog
Statement on Health Equity on the Occasion of the UNGA 77
Sep 23, 2022
Building Back Better after the COVID-19 Pandemic: Strengthening Pediatric Immunization Programs in Europe
Sep 21, 2022

World Bank  [to 024 Sep 2022]
Selected News, Announcements
From Double Shock to Double Recovery: Health Financing in the Time of COVID-19
In the wake of global economic shocks, without bold choices, many countries will be unable to make the necessary investments to strengthen public health preparedness and response capabilities and make...
Date: September 22, 2022 Type: Publication

Evidence-based approach helps artisanal and small-scale miners weather COVID-19 impacts
Challenge The emergence of the COVID-19 pandemic in early 2020 threatened people’s lives and livelihoods. The World Bank estimated that the pandemic could push at least 71 million people into extreme poverty...
Date: September 22, 2022 Type: Result Brief

Second Joint Statement by the Heads of FAO, IMF, WBG, WFP, and WTO on the Global Food Security and Nutrition Crisis
Food and Agriculture Organization of the United Nations (FAO) Director General Qu Dongyu, International Monetary Fund (IMF) Managing Director Kristalina Georgieva, World Bank Group (WBG) President David...
Date: September 21, 2022 Type: Statement

World Customs Organization – WCO [to 24 Sep 2022]
http://www.wcoomd.org/
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE) [to 24 Sep 2022]
https://www.oie.int/en/
Press Releases, Statements
Joint Press Release
The Global Leaders Group host side event at UN General Assembly on Antimicrobial Resistance (AMR)
New York – Today, The Global Leaders Group co-chairs, Their Excellencies Sheikh Hasina, Prime Minister of Bangladesh and Mia Amor Mottley, Prime Minister of Barbados, hosted a UN General Assembly side event to discuss and address antimicrobial resistance (AMR) with Heads of Government and State, government Ministers and relevant stakeholders. The event was moderated by Global Leaders Group member Christopher Fearne, Deputy Prime Minister and Minister of Health of Malta...
Published on 22 September 2022

News
Collaborating for better global health: New Tripartite Operational Tools
Published on 21 September 2022
Greater collaboration across sectors is needed to protect everyone’s health from the impacts of zoonotic diseases, as strongly reminded by recent emerging diseases with an animal origin. New operational tools are available to support countries in achieving this One Health collaboration in the field.
Agency heads call for urgent action to address global food security crisis
21 September 2022
Heads of the UN Food and Agriculture Organization, International Monetary Fund, World Bank Group, World Food Programme and the WTO issued a joint statement on 21 September calling on governments to take urgent and coordinated action to address the acute food crisis. They underscored the importance of maintaining momentum on ongoing work and building resilience for the future, which “will require a continued comprehensive and coordinated effort to support efficient production and trade, improve transparency, accelerate innovation and joint planning and invest in food systems transformation”. 

Announcement of PDUFA Agreement in Congress Supports Biomedical Innovation, Helps Patients
September 22, 2022

Facts and Figures 2022: The Pharmaceutical Industry and Global Health
20 September 2022
International Alliance of Patients’ Organizations – IAPO [to 24 Sep 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

PhRMA [to 24 Sep 2022]
http://www.phrma.org/
Press Releases
No new digest content identified.

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
20 September 2022

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - No new digest announcements identified

Biological E
News - No new digest announcements identified

BioNTech
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified
Cinnagen
Recent News  -  Website not responding at inquiry

Clover Biopharmaceuticals - China
News
Sep 20,2022
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate

Sep 20,2022
Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine

Curevac [Bayer Ag – Germany]
News  -  No new digest announcements identified

Gamaleya National Center
Latest News and Events  -  See Russia below.

GSK
Press releases for media
21 September 2022
GSK and Microsoft, in collaboration with the Centre for Health and Disease Studies, launch disease surveillance project in Nepal
New partnership combines expertise across Biopharma and Tech sectors.

IMBCAMS, China
Home  -  Website not responding at inquiry

Janssen/JNJ
Press Releases  -  No new digest announcements identified

Medicago
Media  -  No new digest announcements identified

Merck
News releases
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
Sep 20, 2022

Moderna
Press Releases  -  No new digest announcements identified

Nanogen
News  -  No new digest announcements identified

Novartis
News  -  No new digest announcements identified
Novavax
Press Releases - No new digest announcements identified

Pfizer
Recent Press Releases
09.22.2022
Press Releases
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries

09.19.2022
Press Releases
Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPWBIP
News - No new digest announcements identified

Sinovac
Press Releases
SINOVAC Quadrivalent Influenza Vaccine Is Authorized For Marketing Use in Bangladesh
2022-09-16

SK Biosciences
Press Releases - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Journal Watch

* Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 3
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 9: E817-912 Sep 2022
What We Owe Workers in Health Care Earning Low Wages

If you’re a professional caregiver in the US with colleagues paid a minimum wage, their labor is valued so little that it would be a crime to pay them less. The US Federal Fair Labor Standards Act of 1938 requires employers under its jurisdiction to pay workers at least a federal minimum wage. Yet in most of the US, a living wage is at least twice that amount. Privation, risk of injury and illness, uninsurance, and underinsurance undermine equity for health aides, environmental services workers, nursing and medical assistants, paramedics, and their children in the US. This theme issue investigates what we—as citizens, clinicians of status, and organizations—owe these vulnerable workers, on whose hour-to-hour care of some of our most vulnerable patients we heavily rely and woefully undervalue.

American Journal of Infection Control
September 2022 Volume 50 Issue 9 p969-1076
http://www.ajicjournal.org/current
[Reviewed earlier]
American Journal of Preventive Medicine
September 2022  Volume 63  Issue 3  p313-468
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
September 2022  112(9)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 107 (2022): Issue 3_Suppl (Sep 2022)
https://www.ajtmh.org/view/journals/tpmd/107/3_Suppl/tpmd.107.issue-3_Suppl.xml
Malaria Transmission Blocking Vaccines
[Reviewed earlier]

Annals of Internal Medicine
September 2022  Volume 175, Issue 9
http://annals.org/aim/issue
Original Research
Evaluating the Performance of Centers for Disease Control and Prevention COVID-19 Community Levels as Leading Indicators of COVID-19 Mortality
FREE
Joshua A. Salomon, PhD, Alyssa Bilinski, PhD
Pages:1240–1249

Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France
FREE
Jérémie Botton, PharmD, PhD, Marie Joelle Jabagi, PharmD, PhD, Marion Bertrand, MSc, ... et al.
Pages:1250–1257

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
FREE
Dean Follmann, PhD, Holly E. Janes, PhD, Olive D. Buhule, PhD, Honghong Zhou, PhD, ... et al.
Pages:1258–1265

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial
FREE
ACTIV-3/TICO Study Group
Pages:1266–1274

Research and Reporting Methods
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
FREE
Lisa M. DeTora, PhD, MS, Dikran Toroser, PhD, Angela Sykes, MA, MPhil, Christine Vanderlinden, PhD, ... et al.
Pages:1298–1304

Clinical Guidelines
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
FREE
Lise J. Estcourt, MB BChir, DPhil, Claudia S. Cohn, MD, PhD, Monica B. Pagano, MD, Claire Iannizzi, MSc, ... et al.
Pages:1310–1321

Position Papers
Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of Physicians
FREE
Lisa Soleymani Lehmann, MD, PhD, Lois Snyder Sulmasy, JD, Wylie Burke, MD, PhD, ... et al.
Isaac O. Opole, MBChB, PhD, Noel N. Deep, MD, George M. Abraham, MD, MPH, Joel Burnett, MD, ... et al.
Pages:1322–1323

Editorials
The Fast and the Furious: Chasing a Clinical Niche for COVID-19 Convalescent Plasma
FREE
Jason V. Baker, MD, MS, H. Clifford Lane, MD
Pages:1332–1334

Artificial Intelligence – An International Journal
Volume 310  September 2022
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 24 Sep 2022)
[No new digest content identified]

BMJ Global Health
August 2022 - Volume 7 - 8
https://gh.bmj.com/content/7/8
Editorial
Reimagining human rights in global health: what will it take? (29 August, 2022)
Facilitating access to medicines and continuity of care for Ukrainian refugees: exceptional response or the promise of more inclusive healthcare for all migrants? (25 August, 2022)
Rajat Khosla, Pascale Allotey, Sofia Gruskin

Protracted armed conflict and maternal health: a scoping review of literature and a retrospective analysis of primary data from northwest Syria (30 August, 2022)
Saleh Aljadeeah, Joris Michielsen, Raffaella Ravinetto, Sally Hargreaves, Veronika J. Wirtz, Oliver Razum, Federico Gobbi, Karina Kielmann

Protracted armed conflict and maternal health: a scoping review of literature and a retrospective analysis of primary data from northwest Syria (30 August, 2022)
Saleh Aljadeeah, Joris Michielsen, Raffaella Ravinetto, Sally Hargreaves, Veronika J. Wirtz, Oliver Razum, Federico Gobbi, Karina Kielmann

An exploration of practices affecting research integrity in global health partnerships (26 August, 2022)
Lindsay Troughton, Angela Obasi

Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya (1 August, 2022)

Managing the challenges associated with decreasing demand for COVID-19 vaccination in Central and West Asia (29 August, 2022)
Alexander Bongers, Giovanna Riggall, Larissa Kokareva, Brian Chin

Exploring the why: risk factors for HIV and barriers to sexual and reproductive health service access among adolescents in Nigeria
Early sexual debut, low educational attainment, history of rape and transactional and intergenerational sex have been associated with HIV infection among Nigerian adolescents, especially females. We sought to ...

Authors: Morenike O. Folayan, Nadia A. Sam-Agudu and Abigail Harrison
Citation: BMC Health Services Research 2022 22:1198
Content type: Research Published on: 23 September 2022

Changes in on-time vaccination following the introduction of an electronic immunization registry, Tanzania 2016-2018: interrupted time-series analysis

Digital health interventions (DHI) have the potential to improve the management and utilization of health information to optimize health care worker performance and provision of care. Despite the proliferation...

Authors: Samantha B. Dolan, Roy Burstein, Jessica C. Shearer, Ngwegwe Bulula, Hil Lyons, Emily Carnahan, Emily Beylerian, Jenny Thompson, Nancy Puttkammer, William B. Lober, Shan Liu, Skye S. Gilbert, Laurie Werner and Tove K. Ryman
Citation: BMC Health Services Research 2022 22:1175
Content type: Research Published on: 20 September 2022

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 24 Sep 2022)
COVID’s collateral damage: likelihood of measles resurgence in the United States

Lockdowns imposed throughout the US to control the COVID-19 pandemic led to a decline in all routine immunizations rates, including the MMR (measles, mumps, rubella) vaccine. It is feared that post-lockdown, t...

Authors: Mugdha Thakur, Richard Zhou, Mukundan Mohan, Achla Marathe, Jiangzhuo Chen, Stefan Hoops, Dustin Machi, Bryan Lewis and Anil Vullikanti
Citation: BMC Infectious Diseases 2022 22:743
Content type: Research Published on: 20 September 2022

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 24 Sep 2022)
Parental waivers to enable adolescent participation in certain forms of health research: lessons from a South African case study

The South African legal framework requires mandatory parental/legal guardian consent for all research with children. Ethics guidelines provide some reprieve by allowing RECs to grant waivers of parental or guardi...

Authors: Ann Strode and Zaynab Essack
Citation: BMC Medical Ethics 2022 23:98
Content type: Debate Published on: 24 September 2022

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 24 Sep 2022)
Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study

The results of a randomised trial showed the safety and efficacy of Gam-COVID-Vac against COVID-19. However, compared to other vaccines used across the globe, the real-world data on the effectiveness of Gam-COVID-Vac, especially against the disease caused by the Delta variant of concern, was limited. We aimed to assess the effectiveness of vaccination mainly conducted with Gam-COVID-Vac in St. Petersburg, Russia.

Authors: Anton Barchuk, Mikhail Cherkashin, Anna Bulina, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, Oksana Stanevich, Dmitriy Skougarevskiy and Artemiy Okhotin

Citation: BMC Medicine 2022 20:312
Content type: Research article Published on: 20 September 2022

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 24 Sep 2022)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 24 Sep 2022)

Quarantine preparedness – the missing factor in COVID-19 behaviour change? Qualitative insights from Australia

A key feature of the global public health response to contain and slow the spread of COVID-19 has been community-based quarantine and self-isolation. As part of The Optimise Study, this research sought to unde...

Authors: Angela Davis, Stephanie Munari, Joseph Doyle, Brett Sutton, Allen Cheng, Margaret Hellard and Lisa Gibbs
Citation: BMC Public Health 2022 22:1806
Content type: Research Published on: 23 September 2022

Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19

Given patient preferences, the choice of delivery modality for vaccines against SARS-CoV-2 has the potential to significantly impact both health and economic consequences of an outbreak of COVID-19. This study...

Authors: Bryan Patenaude and Jeromie Ballreich
Citation: BMC Public Health 2022 22:1792
Content type: Research Published on: 22 September 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 24 Sep 2022)

Promoting trust in research and researchers: How open science and research integrity are intertwined
Proponents of open science often refer to issues pertaining to research integrity and vice versa. In this commentary, we argue that concepts such as responsible research practices, transparency, and open sci...  
Authors: Tamarinde Haven, Gowri Gopalakrishna, Joeri Tijdink, Dorien van der Schot and Lex Bouter  
Citation: BMC Research Notes 2022 15:302  
Content type: Commentary Published on: 20 September 2022

**BMJ Evidence-Based Medicine**  
October 2022 - Volume 27 - 5  
[https://ebm.bmj.com/content/27/5](https://ebm.bmj.com/content/27/5)  
[New issue; No relevant content identified]

**BMJ Open**  
September 2022 - Volume 12 - 9  
[https://bmjopen.bmj.com/content/12/9](https://bmjopen.bmj.com/content/12/9)  
[Reviewed earlier]

**Bulletin of the World Health Organization**  
Volume 100(9); 2022 Sep 1  
[Reviewed earlier]

**Cell**  
Sep 15, 2022 Volume 185 Issue 19 p3459-3638  
[https://www.cell.com/cell/current](https://www.cell.com/cell/current)  
[New issue; No digest content identified]

**Child Care, Health and Development**  
Volume 48, Issue 5 Pages: 659-879 September 2022  
[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**  
Volume 112, Issue 3 Pages: 413-729 September 2022  
[Reviewed earlier]

**Clinical Therapeutics**  
July 2022 Volume 44 Issue 7 p927-1034  
[Reviewed earlier]
**Clinical Trials**  
Volume 19 Issue 4, August 2022  
https://journals.sagepub.com/toc/ctja/19/4  
[Reviewed earlier]

**Conflict and Health**  
http://www.conflictandhealth.com/  
[Accessed 24 Sep 2022]  
[No new digest content identified]

**Contemporary Clinical Trials**  
Volume 120  September 2022  
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/120/suppl/C  
*Short communication  Abstract only*  
**Strategies to improve the recruitment and retention of underserved children and families in clinical trials: A case example of a school-supervised asthma therapy pilot**  
Julia O'Donoghue, Janki Luther, Shushmita Hoque, Raphael Mizrahi, ... Michelle Trivedi  
Article 106884

Research article  Open access  
Konrad Maruszczyk, Olalekan Lee Aiyegbusi, Victor Roth Cardoso, Georgios V. Gkoutos, ... Melanie J. Calvert  
Article 106882

**The CRISPR Journal**  
Volume 5, Issue 4 / August 2022  
https://www.liebertpub.com/toc/crispr/5/4  
[Reviewed earlier]

**Current Genetic Medicine Reports**  
Volume 9, issue 4, December 2021  
https://link.springer.com/journal/40142/volumes-and-issues/9-4  
[Reviewed earlier]

**Current Opinion in Infectious Diseases**  
October 2022 - Volume 35 - Issue 5  
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx  
[Reviewed earlier]
Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 3  Pages: 123-180  September 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 6, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 4  Pages: 853-1126  October 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23  Issue 9  5 September 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 10—October 2022
http://wwwnc.cdc.gov/eid/

Books and Media
Forgotten People, Forgotten Diseases: The Neglected Tropical Diseases and Their Impact on Global Health and Development  [PDF - 354 KB - 1 page]
E. Y. Cramer and A. A. Lover

Epidemics
Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 5  Pages: 1-21  September–October 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Protecting healthy volunteers • IRBs and research biopsies
[Reviewed earlier]

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 23  August 2022
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 4, August 2022
https://academic.oup.com/eurpub/issue/32/4
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (9) 2022
https://www.tandfonline.com/toc/ierv20/current
Article
Making COVID-19 mRNA vaccines accessible: challenges resolved
Sarfaraz K. Niazi
Pages: 1163-1176
Published online: 17 Jun 2022

Review
The omics strategy: the use of systems vaccinology to characterize immune responses to childhood immunization
Review

Expert review on global real-world vaccine effectiveness against SARS-CoV-2
Sunate Chuenkitmongkol, Rontgene Solante, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Dung Do-Van, Masliyana Husin, Kao-Pin Hwang, Sasisopin Kiertiburanakul, Prasad S. Kulkarni, Ping-Ing Lee, Rommel Cristenio Lobo, Cao Huu Nghia, Anna Ong-Lim, Sheamini Sivasampu, Jing Lian Suah, Peter Seah Keng Tok, Guy Thwaites & SEA Vaccine Effectiveness Expert Working Group
Pages: 1255-1268
Published online: 30 Jun 2022

Review

Non-COVID-19 vaccine hesitancy among migrant populations worldwide: a scoping review of the literature, 2000-2020
Pages: 1269-1287
Published online: 08 Jun 2022

Foreign Affairs
Volume 101, Number 5 September/October 2022
https://www.foreignaffairs.com/issues/2022/101/5
[New issue; No relevant content identified]

Forum for Development Studies
Volume 49, 2022 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genetics in Medicines
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 24 Sep 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
(Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice

Introduction

(Re)imagining research, activism, and rights at the intersections of sexuality, health, and social justice
Debolina Dutta, Laura Murray, Elsa Oliveira & Richard Parker
Pages: 2223-2234

ABSTRACT

The Covid-19 pandemic inaugurated a new global order of public life and health marked by death, despair and alienation. As a crisis of a global scale, it made the task of (re)imagination simultaneously necessary and extremely difficult. It is this double bind of the difficulty and imminence of imagination that motivates the curation of this special issue. In this introduction, we map the connections between the theme of this volume and the key ideas that constitute its varied contributions, which we organised under three broad mobilising ideas: Rights and Resilience; Sexuality, Health and Justice; and Politics of Knowledge Production and Collaborations. Contributions cover myriad issues, engage in methodological innovations and play with diverse genres. Alongside more traditional academic writings, there are community-based research papers, activist conversations, visual essays, reflective pieces and interviews. The geographical span of the contributions brings insights from around the world and the number of topics covered in this issue are equally vast including, among others, mental health, disability, environment, sex work, violence, queerness, LGBTQ+ experiences, love and anger. The aim of this special issue, then, is to challenge the Manichean distinctions that are often drawn between research and activism, and by extension, between theory and practice.
Health and Human Rights
Volume 24, Issue 1, June 2022
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 4 - October 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 8, October 2022
https://academic.oup.com/heapol/issue/37/8
ORIGINAL ARTICLES
Assessing the potential of wearable health monitors for health system strengthening in low- and middle-income countries: a prospective study of technology adoption in Cambodia
Marco Liverani, Por Ir, Pablo Perel, Mishal Khan, Dina Balabanova ...
Health Policy and Planning, Volume 37, Issue 8, October 2022, Pages 943–951,
https://doi.org/10.1093/heapol/czac019

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 24 Sep 2022]
[No new digest content identified]

Human Gene Therapy
Volume 33, Issue 17-18 / September 2022
https://www.liebertpub.com/toc/hum/33/17-18
Reviews
Methods for Extrapolating Survival Analyses for the Economic Evaluation of Advanced Therapy Medicinal Products
Will A.S. Hardy and Dyfrig A. Hughes
Pages:845–856
Published Online:12 July 2022
https://doi.org/10.1089/hum.2022.056
Abstract
There are two significant challenges for analysts conducting economic evaluations of advanced therapy medicinal products (ATMPs): (1) estimating long-term treatment effects in the absence of mature clinical data and (2) capturing potentially complex hazard functions. This review identifies and critiques a variety of methods that can be used to overcome these challenges. The narrative review is informed by a rapid literature review of methods used for the extrapolation of survival analyses in the economic evaluation of ATMPs. There are several methods that are more suitable than traditional parametric
survival modeling approaches for capturing complex hazard functions, including, cure-mixture models and restricted cubic spline models. In the absence of mature clinical data, analysts may augment clinical trial data with data from other sources to aid extrapolation, however, the relative merits of applying methods for including data from different sources is not well understood. Given the high and potentially irrecoverable costs of making incorrect decisions concerning the reimbursement or commissioning of ATMPs, it is important that economic evaluations are correctly specified, and that both parameter and structural uncertainty associated with survival extrapolations are considered. Value of information analyses allow for this uncertainty to be expressed explicitly, and in monetary terms.

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
Humanitarian resistance: Its ethical and operational importance
Russia's invasion of Ukraine and the return of military dictatorship in Myanmar have reminded the world of the importance of humanitarian resistance. In both countries, civilian rescue and relief is being organised by resistance groups that are struggling for victory and humanity in equal measure, and so simultaneously taking sides for human life and human freedom. They are not neutral but they are humanitarian. In many situations, resistance humanitarians are reaching people faster and better than orthodox humanitarians from neutral international agencies.
Hugo Slim
September 20, 2022

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Sep 13, 2022 Volume 55 Issue 9 p1515-1750
https://www.cell.com/immunity/current Articles
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 24 Sep 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 24 Sep 2022]
[No new digest content identified]
**Diagnostic Excellence**

Harvey V. Fineberg, MD, PhD; Susan Song, MPH; Tommy Wang, PhD


This Viewpoint concludes the series on diagnostic excellence and explores the future of diagnostics that emphasize prediction of future health state rather than identification of current disease.

**The FDA and the Clinical Community**

Robert M. Califf, MD

free access
This Viewpoint from FDA Commissioner Robert Califf, MD, emphasizes the agency’s overarching priorities focused on helping to create a system that benefits from abundant high-quality evidence in a transparent environment.

**Special Communication**

**The US Medicaid Program Coverage, Financing, Reforms, and Implications for Health Equity**
Julie M. Donohue, PhD; Evan S. Cole, PhD; Cara V. James, PhD; et al.

This Special Communication describes Medicaid eligibility, enrollment, and spending as well as examines areas of Medicaid policy, Medicaid expansion, racial and ethnic health disparities, and the potential to achieve health equity.

**Editorial**

**Medicaid as a Driver of Health Equity**
Alice Hm Chen, MD, MPH; Mark A. Ghaly, MD, MPH

**The FDA and the Clinical Community**
Robert M. Califf, MD

This Viewpoint from FDA Commissioner Robert Califf, MD, emphasizes the agency’s overarching priorities focused on helping to create a system that benefits from abundant high-quality evidence in a transparent environment.

**JAMA Pediatrics**
September 2022, Vol 176, No. 9, Pages 837-952
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

**JBI Evidence Synthesis**
September 2022 - Volume 20 - Issue 9
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

**Journal of Adolescent Health**
September 2022 Volume 71 Issue 3 p251-380
https://www.jahonline.org/current
[New issue; No digest content identified]

**Journal of Artificial Intelligence Research**
Vol. 74 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

**Journal of Community Health**
Volume 47, issue 5, October 2022  
[Reviewed earlier]

**Journal of Development Economics**
Volume 158  September 2022  
[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**
Volume 17 Issue 4, October 2022  
http://journals.sagepub.com/toc/jre/current  
[Reviewed earlier]

**Journal of Epidemiology & Community Health**
September 2022 - Volume 76 - 9  
https://jech.bmj.com/content/76/9  
[New issue; No digest content identified]

**Journal of Evidence-Based Medicine**
Volume 15, Issue 2  Pages: 73-179  June 2022  
https://onlinelibrary.wiley.com/toc/17565391/current  
[Reviewed earlier]

**Journal of Global Ethics**
Volume 18, Issue 1, 2022  
http://www.tandfonline.com/toc/rjge20/current  
*Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications*  
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**
Volume 33, Number 3, August 2022  
https://muse.jhu.edu/issue/48370  
*Table of Contents*  
[Reviewed earlier]
Journal of Immigrant and Minority Health
Volume 24, issue 5, October 2022
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022 - Issue 3
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 225, Issue 12, 15 June 2022
https://academic.oup.com/jid/issue/225/12
[Reviewed earlier]

Journal of International Development
Volume 34, Issue 6  Pages: 1069-1255  August 2022
https://onlinelibrary.wiley.com/toc/10991328/current
[Reviewed earlier]

Journal of Medical Ethics
September 2022 - Volume 48 - 9
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
September 2022  Volume 248  p1-136
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 24 Sep 2022]
[No new digest content identified]
Journal of Public Health Management & Practice
September/October 2022 - Volume 28 - Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 2, June 2022
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
September 2022  Volume 19  Issue 194
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 29, Issue 6, August 2022
https://academic.oup.com/jtm/issue

Editorial
Escalating the 2022 Hajj during the third year of the COVID-19 pandemic
Jaffar A Al-Tawfiq, Rana F Kattan, Ziad A Memish
Journal of Travel Medicine, Volume 29, Issue 6, August 2022, taac059,
https://doi.org/10.1093/jtm/taac059

The escalation of the number of pilgrims for the 2022 Hajj season comes as KSA had succeeded in reaching an excellent percentage in vaccine coverage and subsequently eased the restrictions. KSA adopted an extensive surveillance, implemented risk mitigation, and maximized COVID-19 vaccines coverage.

Perspective
Management of cross-border mobilities during the SARS-CoV-2 pandemic in Europe and implications for public health provision to migrants
Alena Kamenshchikova, PhD, Sally Hargreaves, PhD, Clare I R Chandler, PhD
Journal of Travel Medicine, Volume 29, Issue 6, August 2022, taac093,
https://doi.org/10.1093/jtm/taac093

Although many countries introduced border-control measures to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), migrants on the move, like labour migrants and asylum seekers were trapped within the developing border politics. Here, we discuss how pre-existing
gaps in international public health infrastructures have positioned migrants at a higher risk of SARS-CoV-2.

**Rapid Communication**

**Potential for monkeypox exportation from West and Central Africa through global travel networks**

Get access

Natalie H Au, MSc, Mariana Torres Portillo, MD, MSc, Anindita Marwah, MPH, Andrea Thomas-Bachli, DVM, PhD, P Alex Demarsh, MSc ...  
Journal of Travel Medicine, Volume 29, Issue 6, August 2022, taac072,  
https://doi.org/10.1093/jtm/taac072

**Impact of national lockdown on the suspected SARS-CoV-2 epidemic in terms of the number of fever cases in North Korea**

Changhee Han, BA, Sukhyun Ryu, MD, PhD, Hyewon Shin, Dasom Kim, MPH, Charin Modchang, PhD  
Journal of Travel Medicine, Volume 29, Issue 6, August 2022, taac090,  
https://doi.org/10.1093/jtm/taac090

After reopening the border, North Korea was experiencing community transmission of SARS-CoV-2 and implemented a nationwide lockdown. We estimated that the mean transmissibility declined to <1 within 5 days after the lockdown and that the lockdown was associated with a moderate decrease in transmissibility by 11% (95% confidence interval, 6–17%).

**Journal of Virology**

Volume 96 Number 16 August 2022  
http://jvi.asm.org/content/current  
[Reviewed earlier]

**The Lancet**

Sep 24, 2022 Volume 400 Number 10357 p973-1078, e9  
https://www.thelancet.com/journals/lancet/issue/current  
[New issue; No digest content identified]

**The Lancet Child & Adolescent Health**

Sep 2022 Volume 6 Number 9 p593-666  
https://www.thelancet.com/journals/lanchi/issue/current  
[Reviewed earlier]

**Lancet Digital Health**

Sep 2022 Volume 4 Number 9 e627-e697  
https://www.thelancet.com/journals/landig/issue/current  
[Reviewed earlier]

**Lancet Global Health**

Sep 2022 Volume 10 Number 9 e1209-e1359
The case for lotteries as a tiebreaker of quality in research funding

More funders should consider using randomization to choose grant recipients when decisions are too close to call.
Nature Biotechnology
Volume 40 Issue 9, September 2022
https://www.nature.com/nbt/volumes/40/issues/9
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 24 Sep 2022)
[No new digest content identified]

Nature Genetics
Volume 54 Issue 9, September 2022
https://www.nature.com/ng/volumes/54/issues/9
[Reviewed earlier]

Nature Human Behaviour
Volume 6 Issue 9, September 2022
https://www.nature.com/nathumbehav/volumes/6/issues/9
Review Article 19 Sept 2022
The latent structure of global scientific development
By examining the scientific output of each country, Ahn et al. reveal a three-cluster structure of global science.
Lili Miao, Dakota Murray, Yong-Yeol Ahn
Article 02 Jun 2022
Abstract
Science is essential to innovation and economic prosperity. Although studies have shown that national scientific development is affected by geographic, historic and economic factors, it remains unclear whether there are universal structures and trajectories of national scientific development that can inform forecasting and policy-making. Here, by examining the scientific ‘exports’—publications that are indexed in international databases—of countries, we reveal a three-cluster structure in the relatedness network of disciplines that underpin national scientific development and the organization of global science. Tracing the evolution of national research portfolios reveals that while nations are proceeding to more diverse research profiles individually, scientific production is increasingly specialized in global science over the past decades. By uncovering the underlying structure of scientific development and connecting it with economic development, our results may offer a new perspective on the evolution of global science.

Resource 23 May 2022
Global survey on COVID-19 beliefs, behaviours and norms
This Resource describes the data from a survey on COVID-19 related behaviours, beliefs and norms. From July 2020 to March 2021, the authors fielded a global survey on people’s baseline beliefs, behaviours and norms related to COVID-19 in 67 countries, yielding over 2 million responses.
Avinash Collis, Kiran Garimella, Dean Eckles
Abstract
Policy and communication responses to COVID-19 can benefit from better understanding of people's baseline and resulting beliefs, behaviours and norms. From July 2020 to March 2021, we fielded a global survey on these topics in 67 countries yielding over 2 million responses. This paper provides an overview of the motivation behind the survey design, details the sampling and weighting designed to make the results representative of populations of interest and presents some insights learned from the survey. Several studies have already used the survey data to analyse risk perception, attitudes towards mask wearing and other preventive behaviours, as well as trust in information sources across communities worldwide. This resource can open new areas of enquiry in public health, communication and economic policy by leveraging large-scale, rich survey datasets on beliefs, behaviours and norms.

Nature Medicine
Volume 28 Issue 9, September 2022
https://www.nature.com/nm/volumes/28/issues/9
Editorial 21 Sept 2022
Patient safety needs innovation
Advances in the applications of artificial intelligence and other technologies in health and medicine require rethinking of what patient safety means.

Comment 15 Sept 2022
An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials
Results from clinical trials can be deemed trustworthy only if they are properly conducted and their methods are fully reported. The SPIRIT and CONSORT checklists, which have improved clinical trial design, conduct and reporting, are being updated to reflect recent advances and improve the assessment of healthcare interventions.
Sally Hopewell, Isabelle Boutron, David Moher

Comment 22 Jul 2022
A blueprint for eliminating cholera by 2030
Cholera is endemic in 47 countries, but deaths from this disease can be eliminated with a package of low-cost measures implemented by community healthcare workers.
Md Taufiqul Islam, Allen G. Ross, Firdausi Qadri

Review Article 15 Sept 2022
Multimodal biomedical AI
Multimodal artificial intelligence models could unlock many exciting applications in health and medicine; this Review outlines the most promising uses and the technical pitfalls to avoid.
Julián N. Acosta, Guido J. Falcone, Eric J. Topol

Article Open Access 15 Sept 2022
A digital mask to safeguard patient privacy
A deep-learning algorithm that removes patient-identifying information from facial images, while retaining sufficient information for accurate disease diagnosis, has the potential to protect patient privacy and facilitate public acceptance of facial imaging for use in digital medicine.
Yahan Yang, Junfeng Lyu, Haotian Lin
Perspective

**Fundamentals of Health Law: The Law of Licensure and Quality Regulation**

N. Cortez

[Accessed 24 Sep 2022]

[No new digest content identified]
Pathogen evolution during vaccination campaigns
Troy Day, David A. Kennedy, Andrew F. Read, Sylvain Gandon
Essay | published 23 Sep 2022 PLOS Biology
https://doi.org/10.1371/journal.pbio.3001804

Abstract
Following the initiation of the unprecedented global vaccination campaign against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), attention has now turned to the potential impact of this large-scale intervention on the evolution of the virus. In this Essay, we summarize what is currently known about pathogen evolution in the context of immune priming (including vaccination) from research on other pathogen species, with an eye towards the future evolution of SARS-CoV-2.

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 24 Sep 2022)

Review
Population genetic models for the spatial spread of adaptive variants: A review in light of SARS-CoV-2 evolution
Margaret C. Steiner, John Novembre
| published 22 Sep 2022 PLOS Genetics
https://doi.org/10.1371/journal.pgen.1010391

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 24 Sep 2022)
[No new digest content identified]

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 24 Sep 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 24 Sep 2022]
Research Article
Motivational factors were more important than perceived risk or optimism for compliance to infection control measures in the early stage of the COVID-19 pandemic
Bjørn Sætrevik, Sebastian B. Bjørkheim
| published 23 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274812

Global mapping of epidemic risk assessment toolkits: A scoping review for COVID-19 and future epidemics preparedness implications
Factors underlying COVID-19 vaccine and booster hesitancy and refusal, and incentivizing vaccine adoption
Neil G. Bennett, David E. Bloom, Maddalena Ferranna
Research Article | published 22 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274529

What message appeal and messenger are most persuasive for COVID-19 vaccine uptake: Results from a 5-country survey in India, Indonesia, Kenya, Nigeria, and Ukraine
Rupali J. Limaye, Kristian Balgobin, Alexandra Michel, Gretchen Schulz, Daniel J. Erchick
Research Article | published 21 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274966

Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries
Francesca Agosti, Veronica Toffolutti, Nicolò Cavalli, Sanna Nivakoski, Massimiliano Mascherini, Arnstein Aassve
Research Article | published 21 Sep 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0273555

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 24 Sep 2022]

Pearls
Human monkeypox: A review of the literature
Rozana El Eid, Fatima Allaw, Sara F. Haddad, Souha S. Kanj
| published 22 Sep 2022 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1010768

PNAS - Proceedings of the National Academy of Sciences of the United States
August 30, 2022 | vol. 119 | no. 35
Research Article August 23, 2022Coronavirus (COVID-19)
Significant impacts of the COVID-19 pandemic on race/ethnic differences in US mortality
The coronavirus 2019 (COVID-19) pandemic triggered global declines in life expectancy. The United States was hit particularly hard among high-income countries. Early data from the United States showed that these losses varied greatly by race/ethnicity in ...
José Manuel Aburto, Andrea M. Tilstra, [...] Jennifer Beam Dowd

Research Article August 22, 2022
Wildlife susceptibility to infectious diseases at global scales
Ángel L. Robles-Fernández, Diego Santiago-Alarcon and Andrés Lira-Noriega
Significance
Previous studies have investigated how environmental, phylogenetic, and geographic variables
determine pathogen infection, particularly for human zoonosis. Yet, none of those previous studies
have provided a methodology that can be applied to a broad array of host–pathogen systems. Here,
we provide a machine learning approach that can integrate different explanatory variables and be
applied to any multihost–multipathogen system. Our results agree with the known ecology of each
analyzed system and provide a tool that can help discovering potential host species and novel
geographical hot spots for a pathogen. Thus, it can help guiding sampling decisions in terms of both
host species and geographical locations. Finally, this tool can be applied at different spatial scales with
few incidence data.

Prehospital & Disaster Medicine
Volume 37 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 162  September 2022
[Reviewed earlier]

Proceedings of the Royal Society B
14 September 2022  Volume 289  Issue 1982
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 210  Pages 1-162 (September 2022)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 4, July/August 2022
https://journals.sagepub.com/toc/phrg/137/4
[Reviewed earlier]
Research article First published 14 June, 2022pp. 265–280
**Informed consent in a tuberculosis genetic study in Cameroon: information overload, situational vulnerability and diagnostic misconception**

Research article First published 7 July, 2022pp. 281–303
**Can an ethics code help to achieve equity in international research collaborations? Implementing the global code of conduct for research in resource-poor settings in India and Pakistan**
Kate Chatfield et al.

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 24 Sep 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 42, Issue 8 Pages: 1603-1890 August 2022
https://onlinelibrary.wiley.com/toc/15396924/current
**Special Issue: Machine Learning and Other Information Analyses for Risk in Social Networks**
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 24 Sep 2022]
[No new digest content identified]
Public access is not equal access
Sudip Parikh Shirley M. Malcom and Bill Moran

On 25 August, the White House Office of Science and Technology Policy provided guidance for scientific publishing aimed at making publications and their supporting data—the products of federally funded research—publicly available without an embargo by the end of 2025. The American Association for the Advancement of Science (AAAS, the publisher of Science and the Science family of journals) strongly supports this guidance. As written, several paths to public access remain possible. It will matter greatly to the scientific enterprise which become predominant.

As a scientific membership organization, AAAS looks at public access through the lens of scientists and engineers. We have experimented with various public access models over the past decade. The Science family has five subscription journals that libraries pay for access to content, and one journal for which authors pay an “article processing charge” to make the version of record of their paper freely available [“gold open access (OA)“]. All six journals publish excellent science and influential analyses, but their sustainability models differ. Each model supports the high quality that authors, readers, librarians, and funders expect us to provide through rigorous peer review shepherded by professional editors, careful editing, access to all relevant data, striking and informative visuals, and an engaging website.

Importantly, we put substantial post-publication resources into preventing misinformation by informing accurate coverage of research through mainstream and social media.

From our experience, open and accessible data are essential to scientific integrity and reproducibility, and we require this accessibility immediately upon publication. Public access to trusted scientific information is also important, and situationally appropriate communication of accurate and understandable science with every audience is paramount. When any reader is unable to separate wheat from chaff, we must help by providing expertise to sift well-done from poorly done science.

Public access should foster a diverse universe of authors and readers regardless of their economic circumstances. This drives scientific excellence and public understanding. Some models for public access are bad for inclusivity. Gold OA journals, for which authors pay publication charges, work for senior scientists who are well-funded, tenured, and overwhelmingly male and white, but not so much for early-career scientists who may be poorly funded, not yet tenured, and much more diverse. Also disadvantaged are scientists at smaller schools, including historically Black colleges and universities, and in underfunded disciplines like math and the social sciences. Although it enables “open access” to readers, this model can be inequitable for many scientists and institutions.

Gold OA damages the scientific enterprise when it incentivizes a volume business model in which every paper is a quantum of revenue that must be published somewhere in a publisher’s ecosystem. The perverse incentive for publishers is to accept more papers, which furthers academia’s publish-or-perish mindset, makes predatory publishing more enticing, and dilutes the scientific literature. As a publisher of a gold OA journal, we’ve made the costly decision to maintain editorial quality and not accept papers just to meet financial targets—but we understand the temptation.
As a scientific membership society, AAAS seeks the best path forward for the enterprise it serves. We are actively seeking to balance the tensions between equitable access for readers and equitable access to publishing. As such, Science is made available through progressively priced licenses whereby larger, more research-intensive institutions pay more. We will soon provide immediate public access to all taxpayer-funded research through a policy called “green OA-zero day,” which allows Science authors to post their “author accepted manuscript” (a fully peer-reviewed and revised version), without delay or incurring additional fees, in a public repository of their choice. This approach allows immediate public access without requiring authors to pay a publication charge, while maintaining the ability of Science to fulfill its mission of communicating groundbreaking research discoveries and illuminating the impact of research on society.

AAAS recognizes that its approach is not perfect and may not work for all journals, so we continue to explore other ideas. We are eager to work with the White House, funding agencies, and anyone else to implement policies that optimize equity for authors and readers. In the meantime, our approach ensures that world-changing science is published and placed into the public realm regardless of a scientist’s geographic location, institutional affiliation, academic rank, or identity. We must not sew more structural inequity into the very fabric of the enterprise we seek to improve.

Reports

**Genetic diversity loss in the Anthropocene**
BY Moises Exposito-Alonso, et al.
22 Sep 2022: 1431-1435
A mutations-area relationship predicts substantial declines in genetic diversity with widespread habitat loss.

**Science and Engineering Ethics**
Volume 28, issue 4, August 2022
[Reviewed earlier]

**Science Translational Medicine**
Volume 14| Issue 663| 21 Sep 2022
[New issue; No digest content identified]

**Social Science & Medicine**
Volume 307 August 2022
[Research article  Open access]
**Opt-out policy and its improvements promote COVID-19 vaccinations**
Xin Liu, Ning Zhao, Shu Li, Rui Zheng
Article 115120

[Research article  Full text access]
**African Americans and the COVID-19 pandemic: A qualitative inquiry of preparedness, challenges, and strategies on how we can move forward**
Jennifer Cunningham-Erves, Imari Parham, Leah Alexander, Jamal Moss, ... Jamaine Davis
Article 115185

Research article  Open access

**Attributing public ignorance in vaccination narratives**
Samantha Vanderslott, Luisa Enria, Alex Bowmer, Abass Kamara, Shelley Lees
Article 115152

**Systematic Reviews**
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 24 Sep 2022]
[No new digest content identified]

**Theoretical Medicine and Bioethics**
Volume 43, issue 2-3, June 2022
[Reviewed earlier]

**Travel Medicine and Infectious Diseases**
Volume 49  September–October 2022
[Reviewed earlier]

**Tropical Medicine & International Health**
Volume 27, Issue 9  Pages: i-iv, 753-840  September 2022
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

**Vaccine**
Volume 40, Issue 38  Pages 5539-5650 (9 September 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/38
Research article  Abstract only

**Travel time to health facilities in Papua New Guinea: Implications for coverage and equity in child vaccinations**
Marie Ishida, Navy Mulou, Ajay Mahal
Pages 5556-5561

Research article  Full text access

**Parents’ views on the acceptability of a COVID-19 vaccine for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates**
Research article  Open access

Stamping the vaccine passport? Public support for lifting COVID-19 related restrictions for vaccinated citizens in France, Germany, and Sweden
Florian Stoeckel, Sabrina Stöckli, Joseph Phillips, Benjamin Lyons, ... Jason Reifler
Pages 5615-5620

Value in Health
September 2022  Volume 25  Issue 9  p1463-1662
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles

Selected Research

Study Protocol metrics AWAITING PEER REVIEW
Burden, causes, and risk factors of perinatal mortality in Eastern Africa: a protocol for systematic review and meta-analysis [version 1; peer review: awaiting peer review]
Yohanis Alemeshet Asefa, Lars Åke Persson, Anna C. Seale, Nega Assefa

Peer Reviewers Invited
Funder
Bill and Melinda Gates Foundation
PUBLISHED 23 Sep 2022

medRxiv
https://www.medrxiv.org/content/about-medrxiv

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Selected Research

Genomic analysis of early spread of monkeypox virus in Washington State
Pavitra Roychoudhury, Jaydee Sereewit, Hong Xie, Ethan Nunley, Nicole A.P. Lieberman, Alexander L Greninger
Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trials
David Dunn, Richard Gilson, Sheena McCormack, Laura McCoy
medRxiv 2022.09.20.22276701; doi: https://doi.org/10.1101/2022.09.20.22276701

DEVELOPMENT OF A COMPLEX INTERVENTION PACKAGE FOR DENGUE PREVENTION
R. M. Nayani Umesha Rajapaksha, Chrishantha Abeysena, Aindralal Balasuriya, Nimalka Pannila Hetti, Ajith Alagiyawanna, Suranga Manilgama
medRxiv 2022.06.16.22274559; doi: https://doi.org/10.1101/2022.06.16.22274559 Revision

Comparative epidemic expansion of SARS-CoV-2 variants Delta and Omicron in Amazonas, a Brazilian setting with high levels of hybrid immunity
medRxiv 2022.09.21.22280193; doi: https://doi.org/10.1101/2022.09.21.22280193

Internal and external forces affecting vaccination coverage: modeling the interactions between vaccine hesitancy, accessibility, and mandates
Kerri-Ann Anderson, Nicole Creanza
medRxiv 2022.09.20.22280174; doi: https://doi.org/10.1101/2022.09.20.22280174

Research Mentorship in Low and Middle-Income Countries: A Global Qualitative Evidence Synthesis of Data from a Crowdsourcing Open Call and Scoping Review
Eneyi E. Kpokiri, Kamryn McDonald, Joseph A. Gebreyohannes, Lyda Osorio, Tilak Chandra Nath, Victor A. Talavera-Urdanivia, Pheabian O. Akinwale, Yuka C. Manabe, Barbara Castelnuevo, Weiming Tang, Daniel Yilma, Michael Mihut, Oliver Ezechi, Juliet Iwelunmor, Mirgissa Kaba, Alemseged Abdissa, Joseph D. Tucker

Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States
Seth Flaxman, Charles Whittaker, Elizaveta Semenova, Theo Rashid, Robbie M Parks, Alexandra Blenkinsop, H Juliette T Unwin, Swapnil Mishra, Samir Bhatt, Deepti Gurdasani, Oliver Ratmann
medRxiv 2022.05.23.22275458; doi: https://doi.org/10.1101/2022.05.23.22275458 Revision

The Genomic Landscape of Rare Disorders in the Middle East
medRxiv 2022.09.17.22279590; doi: https://doi.org/10.1101/2022.09.17.22279590
Wastewater based epidemiology beyond SARS-CoV-2: Spanish wastewater reveals the current spread of Monkeypox virus
Inés Girón-Guzmán, Azahara Díaz-Reolid, Pilar Truchado, Albert Carcereny, David García-Pedemonte, Bruno Hernaez, Albert Bosch, Rosa María Pintó, Susana Guix, Ana Allende, Antonio Alcamí, Alba Pérez-Cataluña, Gloria Sánchez

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 24 Sep 2022]

Monkeypox Deaths Demand Understanding of Spectral Theory of infectious disease pathogenesis
Paul Ola
Last edited: Sep 19, 2022 UTC
Medicine and Health Sciences Diseases Life Sciences Immunology and Infectious Disease Immunology of Infectious Disease Virus Diseases
A second United States death from severe outcomes in the face of monkeypox infection has, along with the first and others in Spain, Brazil, India, Ecuador, Peru, Mexico and Cuba confirmed one of the monkeypox predictions of the theory of "The origin of the mysterious multi-country monkeypox outbreak ...
OSF Preprints

Wellcome Open Research [to 24 Sep 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 24 Sep 2022]
Selected Research
Research Article metrics
Revised
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data [version 3; peer review: 2 approved, 1 approved with reservations]
Peer Reviewers Mark Kimathi; Amy Wesolowski; Benjamin J. Cowling
Funders
Wellcome Trust
National Institute for Health Research
Medical Research Council
Foreign, Commonwealth and Development Office
LATEST VERSION PUBLISHED 22 Sep 2022
Learning from Different Nations’ Experiences with COVID-19: Models of Public Inquiry, Methods to Globally Network
Amanda Glassman et al.
September 20, 2022

While all corners of the world have been touched by COVID-19, countries’ experiences with the virus have certainly not been universal. Staggering divergences in outcomes between countries—in terms of lives lost, economic carnage, secondary health losses, learning loss, and social trust and cohesion,...

The CIOMS Cumulative Glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance. It includes links to the reports and, where applicable, provides references to the sources from which the definitions were adopted or modified. Version 2.0 covers the terms included in twelve different CIOMS reports published between 1992 and 2022. It does not cover CIOMS reports on the subjects of ethics, clinical pharmacology, the Medical Dictionary for Regulatory Activities (MedDRA®), or publications resulting from CIOMS Roundtable Discussions (1967-1997).

Civics for Adults: A Guide for Civics Content Providers
September 19, 2022
Reinvigorating civics has become a national and economic security imperative. The urgency requires reaching not just K-12 students but also adults. This guide is for individuals looking to engage in civics conversations and activities with adults.

**Kaiser Family Foundation**  [to 24 Sep 2022]
https://www.kff.org/search/?post_type=press-release
*Press Releases*
*No new digest content identified.*

**ODI [Overseas Development Institute]**  [to 24 Sep 2022]
*Publications*
*No new digest content identified.*

**Pew Research Center**  [to 24 Sep 2022]
https://www.pewresearch.org/
*Latest Publications [Selected]*
*Short Read*  |  Sep 22, 2022
**Gay or bisexual men express concern about monkeypox, are critical of government’s response**
Men who describe themselves as gay or bisexual are more likely to say they have received or intend to get a monkeypox vaccine.

**Rand**  [to 24 Sep 2022]
https://www.rand.org/pubs.html
*Reports, Selected Journal Articles*
*Report*
**Harnessing the Power of Science and Technology Communities for Crisis Response**
In this Perspective, RAND researchers describe how the U.S. Department of Homeland Security could leverage science and technology communities to support the use of science, technology, innovation, and analytical capabilities during crisis response.
*Sep 19, 2022*
Patricia A. Stapleton, Daniel M. Gerstein, Henry H. Willis
The U.S. Department of Homeland Security (DHS) has to respond to crises generated by a variety of threats and hazards, such as natural disasters, terrorist attacks, and public health emergencies. When confronted with such challenges in the past, DHS has relied on scientific and technical advice and solutions to identify gaps in its processes and operations. By leveraging this technical advice and support, DHS seeks to improve its understanding of the homeland security threats that it manages and its mission effectiveness.
To enhance DHS's ability to leverage science and technology communities to support the use of science, technology, innovation, and analytical capabilities during crisis response, RAND researchers conducted a literature review and discussions with subject-matter experts to understand how these capabilities have been used during past national security crises and how they could be used in the future. In this Perspective, the researchers offer a conceptual framework for employment of the
science and technology communities' capabilities during crisis response. They also present five imperatives that should be considered for providing technical support during a crisis and a concept for how to institutionalize that support. These critical elements form the basis for providing quality technical support to crisis leadership.

Urban Institute [to 24 Sep 2022]
https://www.urban.org/publications
New Research Publications

Brief
Publicly Insured and Uninsured Patients Are More Likely Than Other Patients to Be Treated Unfairly in Health Care Settings Because of Their Coverage Type
September 19, 2022

Fact Sheet
Unfair Treatment or Judgment Due to Race and Ethnicity Is as Likely to Come from Health Care Providers as Front Office Staff
September 19, 2022

World Economic Forum [to 24 Sep 2022]
https://www.weforum.org/press/
Media
No new digest content identified.

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.